InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,929.04
(
2.53%
)
US TECH 100
20,223.20
(
0.00%
)
Dow Jones
43,729.93
(
3.57%
)
Brent Oil
74.85
(
-0.30%
)
Bitcoin
75,056.73
(
-0.75%
)
Post# of 253536
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120672
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 144285

Friday, 06/22/2012 10:17:46 AM

Friday, June 22, 2012 10:17:46 AM

Post# of 253536

While I don't think the CRL is the end of the story for Xarelto in ACS…

It may be the end of the story for Xarelto in ACS per se. My guess is that JNJ will decide to refocus on the PCI sub-indication of ACS, which is the subject of a separate NDA submission made in May 2012.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up